Association between anxiety disorder and insulin resistance in middle-aged and elderly

doi:10.3969/j.issn.1004-583X.2021.08.007

Abstract

Abstract:

Objective To explore the correlation between anxiety disorder and insulin resistance(IR) in middle-aged and elderly. Methods A total of 159 patients aged 50 to 80 years who were first diagnosed with anxiety disorder were randomly selected as the study group from January 2019 to December 2019. 150 healthy subjects were randomly selected as the control group at the same time. Demographic data of two groups were collected, and the Hamilton Anxiety Scale(HAMA) was used for grading.Fasting insulin(FINS) and fasting blood glucose(FPG) were measured and compared between groups. Homeostatic model assessment of insulin resistance was used to calculate insulin resistance index(HOMA-IR).Pearson correlation analysis was used to explore relationship between anxiety disorder and IR in middle-aged and elderly.Results FINS, HOMA-IR, HAMA score were significantly higher in study group than in control group (all P<0.05). Pearson correlation analysis showed that HOMA-IR had no significant correlation with HAMA score(r=-0.049, P=0.536).Conclusion The level of IR in middle-aged and elderly with anxiety disorder is higher than in healthy people of the same age, but there is no correlation between IR and the severity of anxiety.

Key words: mental disorders, insulin, blood glucose

CLC Number:

Zhang Ruyang, Feng Qian. Association between anxiety disorder and insulin resistance in middle-aged and elderly[J]. Clinical Focus, 2021, 36(8): 708-712.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.08.007

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I8/708

Figures/Tables 3

References 34

[1]	Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: A cross-sectional epidemiological study[J]. Lancet Psychiatry, 2019, 6(3):211-224. doi: 10.1016/S2215-0366(18)30511-X URL
[2]	Andreescu C, Lee S. Anxiety disorders in the elderly[J]. Adv Exp Med Biol, 2020, 1191:561-576. doi: 10.1007/978-981-32-9705-0_28 pmid: 32002946
[3]	Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders[J]. Proc Natl Acad Sci U S A, 2015, 112(11):3463-3468. doi: 10.1073/pnas.1500877112 pmid: 25733901
[4]	Yaribeygi H, Farrokhi FR, Butler AE, et al. Insulin resistance: Review of the underlying molecular mechanisms[J]. J Cell Physiol, 2019, 234(6):8152-8161. doi: 10.1002/jcp.27603 pmid: 30317615
[5]	Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance[J]. Physiol Rev, 2018, 98(4):2133-2223. doi: 10.1152/physrev.00063.2017 pmid: 30067154
[6]	Adeva-Andany MM, Martinez-Rodriguez J, Gonzalez-Lucan M, et al. Insulin resistance is a cardiovascular risk factor in humans[J]. Diabetes Metab Syndr, 2019, 13(2):1449-1455. doi: S1871-4021(19)30078-5 pmid: 31336505
[7]	Sampath KA, Maiya AG, Shastry BA, et al. Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis[J]. Ann Phys Rehabil Med, 2019, 62(2):98-103. doi: S1877-0657(18)31483-0 pmid: 30553010
[8]	Gluvic Z, Zaric B, Resanovic I, et al. Link between metabolic syndrome and insulin resistance[J]. Curr Vasc Pharmacol, 2017, 15(1):30-39. pmid: 27748199
[9]	Guest PC. Insulin resistance in schizophrenia[J]. Adv Exp Med Biol, 2019, 1134:1-16. doi: 10.1007/978-3-030-12668-1_1 pmid: 30919329
[10]	Liu X, Tang HY, Luo ZC. Insulin resistance and skin diseases[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2020, 42(2):247-250.
[11]	Yazici D, Sezer H. Insulin resistance, obesity and lipotoxicity[J]. Adv Exp Med Biol, 2017, 960:277-304.
[12]	Diehl T, Mullins R, Kapogiannis D. Insulin resistance in Alzheimer's disease[J]. Transl Res, 2017, 183:26-40. doi: 10.1016/j.trsl.2016.12.005 URL
[13]	American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 5th ed. Arlington: American Psychiatric Pulishing, 2013: 160-163.
[14]	Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor[J]. J Neurochem, 1985, 44(6):1771-1778. pmid: 2859355
[15]	Li L, Li X, Zhou W, et al. Acute psychological stress results in the rapid development of insulin resistance[J]. J Endocrinol, 2013, 217(2):175-184. doi: 10.1530/JOE-12-0559 pmid: 23444388
[16]	Wu WL, Cheng CF, Sun WH, et al. Targeting ASIC3 for pain, anxiety, and insulin resistance[J]. Pharmacol Ther, 2012, 134(2):127-138. doi: 10.1016/j.pharmthera.2011.12.009 URL
[17]	Cai W, Xue C, Sakaguchi M, et al. Insulin regulates astrocyte gliotransmission and modulates behavior[J]. J Clin Invest, 2018, 128(7):2914-2926. doi: 10.1172/JCI99366 URL
[18]	Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders[J]. Proc Natl Acad Sci U S A, 2015, 112(11):3463-3468. doi: 10.1073/pnas.1500877112 pmid: 25733901
[19]	Sharma AN, Elased KM, Garrett TL, et al. Neurobehavioral deficits in db/db diabetic mice[J]. Physiol Behav, 2010, 101(3):381-388. doi: 10.1016/j.physbeh.2010.07.002 URL
[20]	Sharma S, Fulton S. Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry[J]. Int J Obes (Lond), 2013, 37(3):382-389. doi: 10.1038/ijo.2012.48 URL
[21]	Konner AC, Hess S, Tovar S, et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis[J]. Cell Metab, 2011, 13(6):720-728. doi: 10.1016/j.cmet.2011.03.021 URL
[22]	Evans MC, Kumar NS, Inglis MA, et al. Leptin and insulin do not exert redundant control of metabolic or emotive function via dopamine neurons[J]. Horm Behav, 2018, 106:93-104. doi: 10.1016/j.yhbeh.2018.10.001 URL
[23]	Lammel S, Steinberg EE, Foldy C, et al. Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons[J]. Neuron, 2015, 85(2):429-438. doi: 10.1016/j.neuron.2014.12.036 URL
[24]	Stuber GD, Stamatakis AM, Kantak PA. Considerations when using cre-driver rodent lines for studying ventral tegmental area circuitry[J]. Neuron, 2015, 85(2):439-445. doi: 10.1016/j.neuron.2014.12.034 URL
[25]	Soto M, Cai W, Konishi M, et al. Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior[J]. Proc Natl Acad Sci U S A, 2019, 116(13):6379-6384. doi: 10.1073/pnas.1817391116 URL
[26]	Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action[J]. Nat Rev Mol Cell Biol, 2006, 7(2):85-96.
[27]	Tully PJ, Harrison NJ, Cheung P, et al. Anxiety and cardiovascular disease risk: A review[J]. Curr Cardiol Rep, 2016, 18(12):120. doi: 10.1007/s11886-016-0800-3 URL
[28]	Adeva-Andany MM, Martinez-Rodriguez J, Gonzalez-Lucan M, et al. Insulin resistance is a cardiovascular risk factor in humans[J]. Diabetes Metab Syndr, 2019, 13(2):1449-1455. doi: S1871-4021(19)30078-5 pmid: 31336505
[29]	Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: The role of glucose in physiological and pathological brain function[J]. Trends Neurosci, 2013, 36(10):587-597. doi: 10.1016/j.tins.2013.07.001 pmid: 23968694
[30]	Grillo CA, Mulder P, Macht VA, et al. Dietary restriction reverses obesity-induced anhedonia[J]. Physiol Behav, 2014, 128:126-132. doi: 10.1016/j.physbeh.2014.01.026 URL
[31]	Kenna H, Hoeft F, Kelley R, et al. Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease[J]. Neurobiol Aging, 2013, 34(3):641-649. doi: 10.1016/j.neurobiolaging.2012.06.006 URL
[32]	Rasgon NL, Mcewen BS. Insulin resistance-a missing link no more[J]. Mol Psychiatry, 2016, 21(12):1648-1652. doi: 10.1038/mp.2016.162 URL
[33]	Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus[J]. Clin Exp Pharmacol Physiol, 2014, 41(9):650-656.
[34]	Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: Minimal model analysis[J]. Metabolism, 2000, 49(10):1255-1260. doi: 10.1053/meta.2000.9515 URL

组别	例数	性别[例(%)]			年龄 (岁)		体质量 (kg)		身高 (m)		BMI (kg/m²)
组别	例数	男	女		年龄 (岁)		体质量 (kg)		身高 (m)		BMI (kg/m²)
研究组	159	70(44.0)	89(56.0)		60.48±7.01		60.48±7.01		1.63±0.07		22.72±1.71
对照组	150	70(46.7)	80(53.3)		59.86±7.55		60.95±7.05		1.64±0.06		22.64±1.77
统计值		χ²=0.217			t=0.671		t=-0.586		t=-1.227		t=0.390
P值		0.649			0.503		0.558		0.221		0.697
组别	例数	TC (mmol/L)		TG (mmol/L)		LDL-C (mmol/L)		HDL-C (mmol/L)		MMSE评分 (分)		HAMD评分 (分)
研究组	159	2.60±0.83		3.70±1.36		2.88±0.64		1.25±0.24		29.04±1.10		1.00±0.71
对照组	150	2.61±0.85		3.70±1.38		2.85±0.63		1.27±0.26		28.96±1.32		0.99±0.72
统计值		t=-0.049		t=0.001		t=0.414		t=-0.468		t=0.566		t=0.163
P值		0.961		0.999		0.679		0.640		0.572		0.870

组别	例数	性别[例(%)]			年龄 (岁)		体质量 (kg)		身高 (m)		BMI (kg/m²)
组别	例数	男	女		年龄 (岁)		体质量 (kg)		身高 (m)		BMI (kg/m²)
研究组	159	70(44.0)	89(56.0)		60.48±7.01		60.48±7.01		1.63±0.07		22.72±1.71
对照组	150	70(46.7)	80(53.3)		59.86±7.55		60.95±7.05		1.64±0.06		22.64±1.77
统计值		χ²=0.217			t=0.671		t=-0.586		t=-1.227		t=0.390
P值		0.649			0.503		0.558		0.221		0.697
组别	例数	TC (mmol/L)		TG (mmol/L)		LDL-C (mmol/L)		HDL-C (mmol/L)		MMSE评分 (分)		HAMD评分 (分)
研究组	159	2.60±0.83		3.70±1.36		2.88±0.64		1.25±0.24		29.04±1.10		1.00±0.71
对照组	150	2.61±0.85		3.70±1.38		2.85±0.63		1.27±0.26		28.96±1.32		0.99±0.72
统计值		t=-0.049		t=0.001		t=0.414		t=-0.468		t=0.566		t=0.163
P值		0.961		0.999		0.679		0.640		0.572		0.870

组别	例数	FPG (mmol/L)	FINS (mmol/L)	HOMA-IR	HAMA 评分
研究组	159	5.40±0.67	7.40±2.01	1.78±0.49	19.67±3.01
对照组	150	5.34±0.60	6.31±1.71	1.50±0.41	1.00±0.29
t值		0.720	2.779	2.894	73.670
P值		0.472	0.006	0.004	0.001

组别	例数	FPG (mmol/L)	FINS (mmol/L)	HOMA-IR	HAMA 评分
研究组	159	5.40±0.67	7.40±2.01	1.78±0.49	19.67±3.01
对照组	150	5.34±0.60	6.31±1.71	1.50±0.41	1.00±0.29
t值		0.720	2.779	2.894	73.670
P值		0.472	0.006	0.004	0.001